ArticleOncoimmunology
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.
Irene Y Cheung et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
28 papers cite it
cites it